Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Recruiting · NCT04918186 · Registry updated 2026-07-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 2 | 2026-07-21 | NCT04918186 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| BioAtla, Inc. | 3 |
| Canadian Cancer Trials Group | 73 |
| Cancer Research Institute, New York City | 3 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| BCCA - Kelowna | Kelowna | Canada | 10 |
| BCCA - Vancouver | Vancouver | Canada | 22 |
| CHUM-Centre Hospitalier de l'Universite de Montreal | Montreal | Canada | 20 |
| Odette Cancer Centre | Toronto | Canada | 20 |
| The University of Chicago Medical Center | Chicago | United States | 33 |
| University Health Network | Toronto | Canada | 52 |